系统性红斑狼疮并发股骨头坏死研究进展
|
摘要
系统性红斑狼疮合并股骨头坏死发生率高,显著影响患者生活质量,且致糖皮质激素使用受限;随着骨免疫学研究进展,系统性红斑狼疮合并股骨头坏死除归因于糖皮质激素应用外,还需考虑疾病本身可能介导的免疫损伤,重视危险因素如抗磷脂抗体阳性等给予的预警信号,早期发现并进行干预治疗。
Patients with systemic lupus erythematosus(SLE) display a higher incidence of osteonecrosis of the femoral head( ONF),which significantly impacts the quality of life and limits the use of glucocorticoids( GCs). With the progress of bone immunology research,the etiology of SLE with ONF could also be attributed to an immune injury induced by SLE itself in addition to the use of GCs. Clinicians should pay attention to warning signals of risk factors such as antiphospholipid antibody positive,and to giving earlier detection and treatment.
Patients with systemic lupus erythematosus(SLE) display a higher incidence of osteonecrosis of the femoral head( ONF),which significantly impacts the quality of life and limits the use of glucocorticoids( GCs). With the progress of bone immunology research,the etiology of SLE with ONF could also be attributed to an immune injury induced by SLE itself in addition to the use of GCs. Clinicians should pay attention to warning signals of risk factors such as antiphospholipid antibody positive,and to giving earlier detection and treatment.
引文
[1]Mont MA,Glueck CJ,Pacheco IH,et al.Risk factors for osteonecrosis in systemic lupus erythematosus[J].J Rheumatol,1997,54(24):654-662.
[2]Mok CC,Lau CS,Wong RW.Risk factors for avascular bone necrosis in systemic lupus erythematosus[J].Br J Rheumatol,1998,96(37):895-900.
[3]李姝玉,胡大伟.系统性红斑狼疮并发无菌性股骨头坏死的相关因素分析[J].中国骨质疏松杂志,2008,14(5):324-327.
[4]Colwell CW,Robinson CA,Stevenson DD,et al.Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy[J].Orthopedics,1996,88(19):941-946.
[5]中华医学会骨科分会显微修复学组,中国修复重建外科专业委员会骨缺损及骨坏死学组.成人股骨头坏死诊疗标准专家共识(2012年版)[J].中华骨科杂志,2012,32(6):606-610.
[6]李子荣,张鹤山.股骨头坏死诊断与治疗的专家建议[J].中华骨科杂志,2007,27(2):146-148.
[7]Tektonidou MG,Moutsopoulos HM.Immunologic factors in the pathogenesisi of ostenonecrosis[J].Orthop Clin N Am,2004,35(3):146-157.
[8]Arron JR,Cboi Y.Bone versus immune system[J].Nature,2000,408(6812):535-536.
[9]Campos LA,Kiss MH,D'Amico EA,et al.Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus[J].Lupus,2003,12(11):820-826s.
[10]Tektonidou MG,Katerina Malagari,Panayiotis G.Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use:A prospective study by magnetic resonance imaging[J].Arthritis&Rheumaology,2003,48(3):732-736.
[11]Mori T,Takeya H,Nishioka J,et al.Beta 2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface[J].Thrombhaemost,1996,75(1):49-55.
[12]Font J,Espinosa G,Tassies D,et al.Effects ofβ2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions[J].Arthritis Rheum,2002,46(12):3283-3289.
[13]Erhan D,Lockshin MD.What is antiphospholipid syndrome?[J]Curr Rheumatol Rep,2004,6(6):451-457.
[14]Weitzmann MN.The role of inflammatory cytokines,the RANKL/OPG Axis and the immunoskeletal interface in physiological bone turnover and osteoporosis[J].Scientifica(Cairo),2013,2013(3):1-28.
[15]Gori F,Hofbauer LC,Dunstan CR,et al.The expression of osteoprotegerin and RANK ligand and the support of osteoclast by stromalosteoblast lineage cells is developmentaly regulated[J].Endocrinology,2000,141(12):4768-4776.
[16]玄敬敬,张源潮.糖皮质激素与系统性红斑狼疮股骨头坏死[J].世界临床药物,2011,32(1):56-62.
[17]赵冯均,单玉兴.无菌性股骨头坏死的免疫学研究进展[J].中国老年学杂志,2015,7(35):1993-1996.
[18]常志芳,冯成龙,史晓霞,等.免疫与骨质疏松的研究进展[J].中国骨质疏松杂志,2015,21(4):508-513.
[19]张立智,蒋垚.骨免疫学研究进展[J].国际骨科学杂志,2009,30(4):218-220.
[20]Sun Y,Zhang CQ,Chen SB,et al.Treatment of femoral head osteonecrosis in patients with systemic lupus erythematosus by free vascularised fibular grafting[J].Lupus,2009,18(12):1061-1065.
[21]汪亮,刘耀升,刘蜀彬.糖皮质激素诱导股骨头坏死发病机制的研究进展[J].中华损伤与修复杂志,2015,10(5):60-66.
[22]Kenzora JE.Ischemic necrosis of femoral head.Part I.Accumulative cell stress:a hypothesis for the etiology of idiopathic osteonecrosis[J].Instr Course Lect,1983,32:242-252.
[23]王冬雪,李桂叶,马丽,等.系统性红斑狼疮并发无菌性股骨头坏死的临床研究[J].中华内科杂志,2009,48(11):926-929.
[24]齐云秋,程敬亮,潘芦翎,等.系统性红斑狼疮患者并发股骨头坏死危险因素研究[J].中华实验外科杂志,2010,27(12):1937-1939.
[25]李桂叶,赵孟君,马丽,等.系统性红斑狼疮并发无菌性骨坏死危险因素的Meta分析[J].中华风湿病学杂志,2010,14(5):312-316.
[26]Rajagopalan S,Somers EC,Brook RD.Endothelial cell apoptosis in systemic lupus erythematosus:a common pathway for abnormal vascular function and thrombosis propensity[J].Blood,2004,103(10):3677-3683.
[27]Chamley LW,Mckay EJ,Pattison NS.Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies:a mechanism for thrombosis[J].Thromb Res,1993,71(2):103-111.
[28]张秀英,高俊发.激素性股骨头坏死患者血流变指标变化及意义[J].中国血液流变学杂志,1999,9(2):127-128.
[29]Lobato-Mendizabal E,Ruiz-Arguelles GJ.Protein C,protein S and thrombomodulin:one of the natural antithrombotic mechanisms[J].Rev Invest Clin,1990,42(1):54-62.
[30]Robak E,Sysa-Jedrzejewska A,Dziankowska B,et al.Association of interferon gamma,tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity[J].Archivum immunologiae et therapiae experimentalis,1998,46(6):375-380.
[31]Manolagas SC,Jilka RL.Bone marrou,cytokines,and bone remodeling.Emerging insights into the pathophysiology of osteoporosis[J].The New England journal of medicine,1995,332(5):305-311.
[32]Frostegard J,Svenungsson E,Wu R,et al.Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations[J].Arthritis and rheumatism,2005,52(1):192-200.
[33]Svenungsson E,Fei GZ,Jensen-Urstad K,et al.TNF-alpha:a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease[J].Lupus,2003,12(6):454-461.
[34]严静霞,高丽霞,靳洪涛.关注系统性红斑狼疮继发性骨质疏松[J].中国骨质疏松杂志,2015,21(7):888-891.
[35]沈敏宁,苏定雷,王小琴.系统性红斑狼疮合并股骨头缺血性坏死临床观察[J].医学综述,2012,18(2):308-309.
[36]Grossman JM,Gordon R,Ranganath VK,et al.American College of Rheumatology 2010 recommenations for the prevention and treatment of glucocorticoid-induced osteoporosis[J].Arthritis care&research,2010,62(11):1515-1526.
[2]Mok CC,Lau CS,Wong RW.Risk factors for avascular bone necrosis in systemic lupus erythematosus[J].Br J Rheumatol,1998,96(37):895-900.
[3]李姝玉,胡大伟.系统性红斑狼疮并发无菌性股骨头坏死的相关因素分析[J].中国骨质疏松杂志,2008,14(5):324-327.
[4]Colwell CW,Robinson CA,Stevenson DD,et al.Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy[J].Orthopedics,1996,88(19):941-946.
[5]中华医学会骨科分会显微修复学组,中国修复重建外科专业委员会骨缺损及骨坏死学组.成人股骨头坏死诊疗标准专家共识(2012年版)[J].中华骨科杂志,2012,32(6):606-610.
[6]李子荣,张鹤山.股骨头坏死诊断与治疗的专家建议[J].中华骨科杂志,2007,27(2):146-148.
[7]Tektonidou MG,Moutsopoulos HM.Immunologic factors in the pathogenesisi of ostenonecrosis[J].Orthop Clin N Am,2004,35(3):146-157.
[8]Arron JR,Cboi Y.Bone versus immune system[J].Nature,2000,408(6812):535-536.
[9]Campos LA,Kiss MH,D'Amico EA,et al.Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus[J].Lupus,2003,12(11):820-826s.
[10]Tektonidou MG,Katerina Malagari,Panayiotis G.Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use:A prospective study by magnetic resonance imaging[J].Arthritis&Rheumaology,2003,48(3):732-736.
[11]Mori T,Takeya H,Nishioka J,et al.Beta 2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface[J].Thrombhaemost,1996,75(1):49-55.
[12]Font J,Espinosa G,Tassies D,et al.Effects ofβ2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions[J].Arthritis Rheum,2002,46(12):3283-3289.
[13]Erhan D,Lockshin MD.What is antiphospholipid syndrome?[J]Curr Rheumatol Rep,2004,6(6):451-457.
[14]Weitzmann MN.The role of inflammatory cytokines,the RANKL/OPG Axis and the immunoskeletal interface in physiological bone turnover and osteoporosis[J].Scientifica(Cairo),2013,2013(3):1-28.
[15]Gori F,Hofbauer LC,Dunstan CR,et al.The expression of osteoprotegerin and RANK ligand and the support of osteoclast by stromalosteoblast lineage cells is developmentaly regulated[J].Endocrinology,2000,141(12):4768-4776.
[16]玄敬敬,张源潮.糖皮质激素与系统性红斑狼疮股骨头坏死[J].世界临床药物,2011,32(1):56-62.
[17]赵冯均,单玉兴.无菌性股骨头坏死的免疫学研究进展[J].中国老年学杂志,2015,7(35):1993-1996.
[18]常志芳,冯成龙,史晓霞,等.免疫与骨质疏松的研究进展[J].中国骨质疏松杂志,2015,21(4):508-513.
[19]张立智,蒋垚.骨免疫学研究进展[J].国际骨科学杂志,2009,30(4):218-220.
[20]Sun Y,Zhang CQ,Chen SB,et al.Treatment of femoral head osteonecrosis in patients with systemic lupus erythematosus by free vascularised fibular grafting[J].Lupus,2009,18(12):1061-1065.
[21]汪亮,刘耀升,刘蜀彬.糖皮质激素诱导股骨头坏死发病机制的研究进展[J].中华损伤与修复杂志,2015,10(5):60-66.
[22]Kenzora JE.Ischemic necrosis of femoral head.Part I.Accumulative cell stress:a hypothesis for the etiology of idiopathic osteonecrosis[J].Instr Course Lect,1983,32:242-252.
[23]王冬雪,李桂叶,马丽,等.系统性红斑狼疮并发无菌性股骨头坏死的临床研究[J].中华内科杂志,2009,48(11):926-929.
[24]齐云秋,程敬亮,潘芦翎,等.系统性红斑狼疮患者并发股骨头坏死危险因素研究[J].中华实验外科杂志,2010,27(12):1937-1939.
[25]李桂叶,赵孟君,马丽,等.系统性红斑狼疮并发无菌性骨坏死危险因素的Meta分析[J].中华风湿病学杂志,2010,14(5):312-316.
[26]Rajagopalan S,Somers EC,Brook RD.Endothelial cell apoptosis in systemic lupus erythematosus:a common pathway for abnormal vascular function and thrombosis propensity[J].Blood,2004,103(10):3677-3683.
[27]Chamley LW,Mckay EJ,Pattison NS.Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies:a mechanism for thrombosis[J].Thromb Res,1993,71(2):103-111.
[28]张秀英,高俊发.激素性股骨头坏死患者血流变指标变化及意义[J].中国血液流变学杂志,1999,9(2):127-128.
[29]Lobato-Mendizabal E,Ruiz-Arguelles GJ.Protein C,protein S and thrombomodulin:one of the natural antithrombotic mechanisms[J].Rev Invest Clin,1990,42(1):54-62.
[30]Robak E,Sysa-Jedrzejewska A,Dziankowska B,et al.Association of interferon gamma,tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity[J].Archivum immunologiae et therapiae experimentalis,1998,46(6):375-380.
[31]Manolagas SC,Jilka RL.Bone marrou,cytokines,and bone remodeling.Emerging insights into the pathophysiology of osteoporosis[J].The New England journal of medicine,1995,332(5):305-311.
[32]Frostegard J,Svenungsson E,Wu R,et al.Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations[J].Arthritis and rheumatism,2005,52(1):192-200.
[33]Svenungsson E,Fei GZ,Jensen-Urstad K,et al.TNF-alpha:a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease[J].Lupus,2003,12(6):454-461.
[34]严静霞,高丽霞,靳洪涛.关注系统性红斑狼疮继发性骨质疏松[J].中国骨质疏松杂志,2015,21(7):888-891.
[35]沈敏宁,苏定雷,王小琴.系统性红斑狼疮合并股骨头缺血性坏死临床观察[J].医学综述,2012,18(2):308-309.
[36]Grossman JM,Gordon R,Ranganath VK,et al.American College of Rheumatology 2010 recommenations for the prevention and treatment of glucocorticoid-induced osteoporosis[J].Arthritis care&research,2010,62(11):1515-1526.